Skip to main content
. 2025 Aug 21;47(1):2547266. doi: 10.1080/0886022X.2025.2547266

Table 1.

Baseline characteristics of training and validation sets in DKD patients.

Parameter ALL (N = 337) Training set (N = 180) Internal validation set (N = 78) External validation set (N = 79) P
Gender, n (%)         0.255
Male 242 (71.81%) 136 (75.56%) 52 (66.67%) 54 (68.35%)  
Female 95 (28.19%) 44 (24.44%) 26 (33.33%) 25 (31.65%)  
Age (years), median [IQR] 52.00 [45.00–59.00] 52.00 [45.00–58.00] 52.50 [45.00–58.75] 53.00 [48.00–60.50] 0.440
BMI (kg/m²), median [IQR] 26.34 [23.72–28.73] 26.17 [23.98–28.37] 26.09 [23.23–28.37] 27.41 [23.33–30.88] 0.136
Hypertension, n (%)         0.010
No 45 (13.35%) 16 (8.89%) 11 (14.10%) 18 (22.78%)  
Yes 292 (86.65%) 164 (91.11%) 67 (85.90%) 61 (77.22%)  
SBP (mmHg), mean ± SD 144.37 ± 23.19 145.70 ± 23.35 140.60 ± 23.38 145.08 ± 22.55 0.257
DBP (mmHg), median [IQR] 83.00 [74.00–91.00] 84.50 [74.00–92.25] 79.50 [74.00–88.00] 85.00 [77.00–92.00] 0.087
MAP (mmHg), mean ± SD 104.63 ± 16.05 104.61 ± 15.19 100.73 ± 14.65 108.54 ± 18.35 0.009
DR, n (%)         0.397
No 168 (49.85%) 95 (52.78%) 34 (43.59%) 39 (49.37%)  
Yes 169 (50.15%) 85 (47.22%) 44 (56.41%) 40 (50.63%)  
RAASi, n (%)         0.440
No 111 (32.94%) 58 (32.22%) 30 (38.46%) 23 (29.11%)  
Yes 226 (67.06%) 122 (67.78%) 48 (61.54%) 56 (70.89%)  
SGLT2i, n (%)         0.001
No 231 (68.55%) 138 (76.67%) 51 (65.38%) 42 (53.16%)  
Yes 106 (31.45%) 42 (23.33%) 27 (34.62%) 37 (46.84%)  
nsMRA, n (%)         0.007
No 250 (74.18%) 142 (78.89%) 60 (76.92%) 48 (60.76%)  
Yes 87 (25.82%) 38 (21.11%) 18 (23.08%) 31 (39.24%)  
TCM, n (%)         0.351
No 327 (97.03%) 175 (97.22%) 74 (94.87%) 78 (98.73%)  
Yes 10 (2.97%) 5 (2.78%) 4 (5.13%) 1 (1.27%)  
Diabetes duration (months)
median [IQR]
116.00 [60.00–168.00] 120.00 [60.00–180.00] 109.00 [55.76–165.00] 108.00 [45.00–156.00] 0.641

Abbreviations: BMI: Body mass index; SBP: Systolic blood pressure; DBP: Diastolic blood pressure; MAP: Mean arterial pressure; DR: diabetic retinopathy.

RAASi: Renin-angiotensin-aldosterone system inhibitors; SGLT2i: Sodium-glucose cotransporter-2 inhibitors; nsMRA: Non-steroidal mineralocorticoid receptor antagonists; TCM: Traditional Chinese Medicine; IQR: Interquartile range.

*Note: Diabetes duration was calculated from the date of diabetic diagnosis to the kidney biopsy.